<DOC>
	<DOCNO>NCT00003403</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness GPX-100 treating patient solid tumor .</brief_summary>
	<brief_title>GPX-100 Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose GPX-100 outpatient incurable , solid tumor candidate effective systemic therapy . II . Evaluate quantify toxicity GPX-100 patient population . III . Identify change disease status patient population . OUTLINE : This open label , multicenter , dose escalation study . Patients receive GPX-100 IV every 3 week . Patients receive 2 course treatment absence disease progression dose limit toxicity . Treatment may continue 6 course ( 4 course prior doxorubicin ) patient respond non-progressing disease . One patient enter first 3 dose level . Cohorts 3-6 patient enter subsequent dose level . The maximum tolerated dose GPX-100 define dose 2 instance dose limit toxicity observe 6 patient . PROJECTED ACCRUAL : A maximum 30 patient accrue study .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Incurable , solid tumor patient candidate effective systemic therapy Progressive disease define 25 % increase diameter measurable lesion appearance new lesion PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : Greater 16 week Hematopoietic : WBC least 4000/mm3 Platelet count least 125,000/mm3 Hemoglobin least 8 g/dL Hepatic : Bilirubin within normal limit SGOT great 1.5 time normal ( 2.5 time normal disease involvement ) Alkaline phosphatase great 2.5 time normal PT PTT less 1.5 time normal Renal : Creatinine great 1.5 time normal Creatinine clearance least 60 mL/min Cardiovascular : No history congestive heart failure , active ischemic heart disease , uncontrolled hypertension No myocardial infarction within past 6 month Other : Not pregnant nursing ( negative pregnancy test require ) Fertile patient must use effective contraception No weight loss 10 % past 3 month No frequent vomit No severe anorexia PRIOR CONCURRENT THERAPY : Biologic therapy : Prior biologic therapy allow No concurrent immunotherapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover No great 300 mg/m2 cumulative dose doxorubicin No concurrent chemotherapy Endocrine therapy : At least 4 week since prior hormone therapy No concurrent anticancer hormone therapy Concurrent corticosteroid allow Radiotherapy : At least 4 week since prior radiotherapy recover No concurrent radiotherapy Surgery : Not specify Other : At least 4 week since prior investigational drug therapy No concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2001</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>